Mycovia Pharmaceuticals to Present at 2019 BIO Investor Forum

CEO Patrick Jordan to highlight the need for increased industry focus and investment in advancing women’s health

Company selected to present as a “Buzz of BIO” Late Stage Leader

Durham, N.C. – October 21, 2019 – Mycovia Pharmaceuticals, Inc. (“Mycovia”) today announced that Chief Executive Officer Patrick Jordan will present at the 2019 BIO Investor Forum being held October 22-23 at the Westin St. Francis in San Francisco, Calif. The BIO Investor Forum, an international investor conference focused on early and established private companies as well as emerging public companies, brings together leaders from the biotechnology, pharmaceutical and investment communities. Mycovia earned the opportunity to present at the conference through the “Buzz of BIO” competition, as the company was recognized as a Late Stage Leader by popular vote in September.

Mr. Jordan’s remarks will focus on the need for an increase in innovation in women’s health and how future growth in the category will be driven by addressing not just women’s physical and reproductive needs, but also social and cultural needs over their lifetimes. The presentation will take place at 10:30 a.m. PST on Wednesday, October 23, 2019 in the Westin’s Elizabethan Room B.

Mycovia’s lead product, VT-1161, is an oral antifungal product currently in Phase 3 clinical trials for the treatment of Recurrent Vulvovaginal Candidiasis (RVVC), a debilitating, chronic infectious condition that affects nearly 138 million women worldwide each year. More commonly known as chronic yeast infection, RVVC can severely impact a woman’s physical and emotional well-being, and results in billions of dollars in lost productivity. VT-1161 has received the FDA’s Fast Track and Qualified Infectious Disease Product (QIDP) designations, and has the potential to become the first FDA-approved treatment for RVVC.

“While there have been some significant advances, particularly in the areas of reproductive health and oncology, overall investment and innovation in women’s health has historically been limited, resulting in unmet needs for conditions that have significant physical, emotional and financial burden,” says Mr. Jordan. “We are committed to addressing these disparities and are delighted to have the opportunity at this year’s forum to highlight the importance of empowering female patients and inspiring industry leaders to better address the unmet health needs of women.”
VT-1161 is designed to be highly selective, with fewer side effects and improved efficacy over current treatment options. Mycovia is currently conducting global Phase 3 trials of VT-1161 in women with RVVC to support marketing applications in the U.S., the European Union and Japan. Phase 2b studies have shown VT-1161 to have strong safety and efficacy profiles in RVVC patients, with as low as 0 percent recurrence rates through 48 weeks.

Mycovia has recently signed global exclusive licensing agreements to expand access to VT-1161 in other parts of the world. In October 2019, Mycovia licensed VT-1161 to Gedeon Richter, a Hungary-based leader in women’s health that will commercialize and manufacture the drug in Europe, Latin America, Australia, Russia and the Commonwealth of Independent States. In June 2019, Mycovia licensed VT-1161 to Jiangsu Hengrui Medicine, the largest pharmaceutical company in China and one of the largest in the world, to develop and commercialize VT-1161 in China, including mainland China, Hong Kong, Macau and Taiwan.

About Mycovia Pharmaceuticals
Mycovia Pharmaceuticals has a passion for developing breakthrough therapies in areas of unmet medical need, with an initial focus in women’s health. Our lead product candidate, VT-1161, is a novel, oral therapy for RVVC that is designed to have greater selectivity, fewer side effects and improved efficacy than current treatment options. VT-1161 received FDA Qualified Infectious Disease Product and Fast-Track designations to support its potential as the first FDA-approved treatment for RVVC. Mycovia also recognizes that there is tremendous potential for its oral fungal inhibitors to treat a range of multi-drug resistant fungal pathogens. For more information, please visit www.mycovia.com.

About Recurrent Vulvovaginal Candidiasis
RVVC is a debilitating, chronic infectious condition that affects millions of women. Primary symptoms include vaginal itching, burning, irritation and inflammation. Some women may experience abnormal vaginal discharge and painful sexual intercourse or urination, causing variable but often severe discomfort and pain. RVVC impacts quality of life, to a degree comparable to asthma and worse than diseases such as headache and migraine.

Contacts
Mycovia Pharmaceuticals, Inc.
Tiffany Ahlers, 919-467-8539
tahlers@mycovia.com

Media
FleishmanHillard
Anuj Baveja, 919-334-3782
anuj.baveja@fleishman.com

###